Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Becton, Dickinson and Company

Scanwell Health

Cytognos S.L.

GalaFLEX by BD

FlowJo

GSL Solutions, Inc.

BD Biosciences

BD-Canada

BD Rowa 

BD Rowa Germany

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
See community guidelines here:  https://tinyurl.com/yunjmzkx

Vicarious Surgical

U.S. Department of Defense

Global Health Investment Fund (GHIF)

Steris

Apax Partners

At BD, innovation is everyone’s responsibility – from R&D veterans to new engineers to those in completely different roles. Hear R&D director Baiju Babu discuss why it’s important to keep an open mind and make innovation fun. 
#NationalEngineersWeek #Eweek2024 #medtech #BDInnovator 

Champ Davis can easily and quickly describe BD in one word: impactful. But after speaking with him for any length of time, it’s clear that he values his career at the company for so many additional reasons. 
 
Champ says, “One of the things I love about BD is the level of accountability that everyone here holds themselves to. Everyone owns their space, their role, their business, how they show up to work. The culture here allows me to engage more, do more to support the business cross functionally, and keep applying a growth mindset to all I do.”

To meet more makers of possible, visit our blog: https://bit.ly/3MQcl8Z 
 
#JoinBD #proudtobeBD #makersofpossible

BD has partnered with Camtech Health to offer Singapore’s first-ever self-collection option for HPV cervical cancer testing. Time constraints, embarrassment, fear and inconvenience are among the key barriers to screening and before now, Singapore only offered HPV testing via hospital or clinic settings. 
In Singapore, cervical cancer ranks as the 10th most frequent cancer among women and the fourth most frequent cancer among women between 30 and 39 years of age. Cervical cancer is preventable, precancer is curable, and programs like this helps to support the national goal of cervical cancer elimination. Self-collection affords women greater access to HPV testing by enabling them to collect a sample in privacy at a time and place of their choosing. https://bit.ly/3UJ40be

#cervicalcancer #healthaccess #healthequity #HPV #Singapore

We’re thrilled to announce that Rachelle Landry, MBA, BSN, RN, FACHE, LSSYB, CLHP, one of BD’s nurse leaders, has been recognized as one of the “Most Influential Women in Health IT” in 2024 by HIMSS. 

Join us in celebrating Rachelle’s dedication to helping make medication management safer, simpler and smarter, and read more in her Nurses in the Flow blog. https://bddy.me/3wkYu4u

#HealthIT #innovation #NursingExcellence #SaferSimplerSmarterHC


msh id	COM:BD
symbol	BDX
name	Becton, Dickinson and Company
homepage url	https://www.bd.com
country	US
sector	Healthcare
industry	Medical - Instruments & Supplies
market	STOCKS
employee count	70K
crunchbase url	-
linkedin url	-
founders	-

market cap	64.7B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	88.5
growth score 28	41.84
growth score 90	36.27
growth score 365	37.59

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.03
growth cost of revenue	0.08
growth depreciation and amortization	-0.01
growth ebitda	0.02
growth ebitda ratio	-0
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-0.04
growth gross profit ratio	-0.06

COM:BD

BD

Last Close

222.39

21/11 20:10

Market Cap

64.70B

Beta: -

Volume Today

1.12M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	16.95B
cost of revenue	16.95B
depreciation and amortization	2.29B
ebitda	4.72B
ebitda ratio	0.24
eps	4.97
eps diluted	4.94
operating expenses	5.75B
operating income	2.11B
operating income ratio	0.11

accounts receivables	-290M
capital expenditure	-874M
cash at beginning of period	1.16B
cash at end of period	1.48B
inventory	3.27B
working capital ttm	616M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-